This segment encompasses the development, manufacturing, and commercialization of proprietary pharmaceutical products, focusing on innovative drug delivery systems and formulations. R&D efforts are directed towards improving the efficacy, safety, and patient adherence of existing therapies, particularly in areas such as anticoagulation, central nervous system disorders, and cardiovascular diseases. Technologies employed include prolonged-release formulations, pre-filled syringes, and other advanced drug delivery platforms. The segment addresses unmet medical needs by providing differentiated products that enhance patient outcomes and quality of life. Rovi's market positioning is strengthened by its expertise in complex formulations and its established distribution network across Europe. Future opportunities lie in expanding the product portfolio through strategic acquisitions and licensing agreements, as well as leveraging its manufacturing capabilities to support contract manufacturing partnerships. Regulatory compliance and adherence to the highest quality standards are paramount in this segment.

This segment focuses on providing contract manufacturing services to other pharmaceutical companies, leveraging Rovi's state-of-the-art manufacturing facilities and expertise in sterile fill-finish operations. R&D activities are geared towards optimizing manufacturing processes, improving product stability, and developing new formulations for client products. Technologies utilized include aseptic processing, lyophilization, and advanced analytical techniques. The segment serves a diverse range of therapeutic areas, including vaccines, biologics, and small molecule drugs. Rovi's contract manufacturing services enable pharmaceutical companies to outsource their manufacturing needs, reducing capital expenditures and accelerating time to market. The company's competitive advantage lies in its ability to handle complex formulations and its commitment to quality and regulatory compliance. Future growth opportunities include expanding its manufacturing capacity, securing new contract manufacturing agreements, and offering value-added services such as formulation development and regulatory support. Partnerships and collaborations with other pharmaceutical companies are essential for driving growth in this segment.